NEW YORK (GenomeWeb News) – Luminex announced after the market closed Thursday that it has received US Food and Drug Administration clearance for its second-generation cystic fibrosis test.

The xTAG Cystic Fibrosis 39 Kit v2 detects 39 CF-causing gene mutations. It is used to screen potential parents to determine if they are carriers of the CF-causing gene mutations, and also can be used as an aid in newborn screening and in confirmatory diagnostic testing in newborns and children, said Luminex.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

Sponsored by

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.

Sponsored by

In this webinar, Michael Quail of the R&D Sequencing team at the Wellcome Trust Sanger Institute will provide an expert perspective on library prep for next-generation sequencing.

Sponsored by

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.